Pharming Group N.V.: Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated

Related Keywords

Netherlands ,National Institutes Of Health ,Maryland ,United States ,United Kingdom ,London ,City Of ,Amsterdam ,Noord Holland ,America ,American ,V Koneti Rao ,Ethan Metelenis ,Heather Robertson ,Michael Levitan ,Virgil Dalm ,Dan Caley ,Anurag Relan ,Linkedin ,Vp Investor Relations Corporate Communications ,Drug Administration ,Nasdaq ,Exchange Commission ,Meeting Of The American Society Hematology ,Prnewswire Pharming Groupnv ,European Union ,European Medicines Agency ,Pharming Group ,Lifespring Life Sciences Communication ,Committee For Medicinal Products Human Use ,Investor Relations Corporate Communications ,Koneti Rao ,Primary Immune Deficiency Clinic ,National Institutes ,American Society ,Principal Investigator ,Consultant Clinical Immunology ,Immunoglobulin Replacement Therapy ,Chief Medical Officer ,New Drug Application ,Prescription Drug User Fee Act ,Marketing Authorisation Application ,Medicinal Products ,Human Use ,Activated Phosphoinositide ,North America ,Middle East ,Annual Report ,Allergy Clin ,Rev Allergy ,Investor Relations ,Corporate Communications ,Spring Life Sciences Communication ,Pharming ,Group ,Nnounces ,Positive ,Interim ,Analysis ,Data ,Rom ,Pen ,Label ,Extension ,Study ,Eniolisib ,Presentation ,4th ,Society ,Hematology ,Nnual ,Meeting ,Exposition ,